Maehara Y, Oki E, Ota M, Harimoto N, Ando K, Nakanishi R
Int J Clin Oncol. 2023; 28(5):613-624.
PMID: 36961615
DOI: 10.1007/s10147-023-02326-w.
Young C, Adler S, Eary J, Lindenberg M, Jacobs P, Collins J
J Nucl Med. 2018; 60(4):492-496.
PMID: 30389817
PMC: 6448462.
DOI: 10.2967/jnumed.118.216994.
Miyamoto Y, Lenz H, Baba H
Expert Rev Clin Pharmacol. 2015; 9(3):355-65.
PMID: 26677869
PMC: 7485169.
DOI: 10.1586/17512433.2016.1133285.
Meike S, Yamamori T, Yasui H, Eitaki M, Matsuda A, Morimatsu M
Mol Cancer. 2011; 10:92.
PMID: 21798026
PMC: 3161955.
DOI: 10.1186/1476-4598-10-92.
Takiuchi H, Kawabe S, Gotoh M, Katsu K
Gastrointest Cancer Res. 2009; 1(5):171-6.
PMID: 19262706
PMC: 2632528.
Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo.
Yasui H, Ogura A, Asanuma T, Matsuda A, Kashiwakura I, Kuwabara M
Br J Cancer. 2008; 99(9):1442-52.
PMID: 18854835
PMC: 2579694.
DOI: 10.1038/sj.bjc.6604720.
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
Temmink O, Emura T, de Bruin M, Fukushima M, Peters G
Cancer Sci. 2007; 98(6):779-89.
PMID: 17441963
PMC: 11158373.
DOI: 10.1111/j.1349-7006.2007.00477.x.
Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.
Tomassini J, Getty K, Stahlhut M, Shim S, Bhat B, Eldrup A
Antimicrob Agents Chemother. 2005; 49(5):2050-8.
PMID: 15855531
PMC: 1087620.
DOI: 10.1128/AAC.49.5.2050-2058.2005.
Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.
Shimamoto Y, Koizumi K, Okabe H, Kazuno H, Murakami Y, Nakagawa F
Jpn J Cancer Res. 2002; 93(7):825-33.
PMID: 12149149
PMC: 5927072.
DOI: 10.1111/j.1349-7006.2002.tb01325.x.
Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
Shimamoto Y, Fujioka A, Kazuno H, Murakami Y, Ohshimo H, Kato T
Jpn J Cancer Res. 2001; 92(3):343-51.
PMID: 11267946
PMC: 5926715.
DOI: 10.1111/j.1349-7006.2001.tb01101.x.
In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors.
Yamada M, Nakagawa H, Fukushima M, Shimizu K, Hayakawa T, Ikenaka K
J Neurooncol. 1998; 37(2):115-21.
PMID: 9524089
DOI: 10.1023/a:1005869226496.
Difference in thymidylate synthetase activity in involved nodes compared with primary tumor in breast cancer patients.
Komaki K, Kamamura Y, Ohmine Y, Sasa M, Tanaka K, Inoue H
Breast Cancer Res Treat. 1995; 35(2):157-62.
PMID: 7647337
DOI: 10.1007/BF00668205.
Effect of guanosine on antitumor activity of fluorinated pyrimidines against P 388 leukemia.
Iigo M, Hoshi A
Cancer Chemother Pharmacol. 1984; 13(2):86-90.
PMID: 6235977
DOI: 10.1007/BF00257120.
Potentiation of the chemotherapeutic action of 5'-deoxy-5-fluorouridine in combination with guanosine and related compounds.
Iigo M, Miwa M, Ishitsuka H, Nitta K
Cancer Chemother Pharmacol. 1987; 19(1):61-4.
PMID: 3028664
DOI: 10.1007/BF00296258.
Sequence and expression of the dCMP deaminase gene (DCD1) of Saccharomyces cerevisiae.
McIntosh E, HAYNES R
Mol Cell Biol. 1986; 6(5):1711-21.
PMID: 3023902
PMC: 367699.
DOI: 10.1128/mcb.6.5.1711-1721.1986.
Potentiation of the antitumor activity of 5-trifluoromethyl-2'-deoxyuridine by the use of depot forms of the parent compound.
Takeda S, Wierzba K, Yamashita J, Matsumoto H, Satake H, Yamada Y
Cancer Chemother Pharmacol. 1992; 30(5):360-4.
PMID: 1505074
DOI: 10.1007/BF00689963.